AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3137773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29672085 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week REACH Forgiveness intervention
Number of subjects: 162
Study 29672085 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week process group
Number of subjects: 162
Study 29672085 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 162
Study 27025451 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretch group (Bartenieff Fundamentals(TM) thigh lift)
Number of subjects: 18
Study 27025451 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretch group (contract‐release‐contract form of PNF)
Number of subjects: 18
Study 27025451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 23616267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific guides (PSGs)
Number of subjects: 128
Study 23616267 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 128
Study 23362285 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiation (within 7 days)
Number of subjects: 27
Study 23362285 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART initiation (after 28 days)
Number of subjects: 27
Study 20033338 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited hiatal dissection combined with myotomy and Dor's procedure (G2)
Number of subjects: 84
Study 20033338 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller's myotomy alone (G3)
Number of subjects: 84
Study 20033338 — intervention group
Group type: COMPARATOR
Intervention: Complete hiatal dissection (G1)
Number of subjects: 84
Study 20033338 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative dysphagia recurrence
Number of subjects: 84
Study 17701189 — intervention group
Group type: EXPERIMENTAL
Intervention: XCaliber pins (Orthofix)
Number of subjects: 50
Study 17701189 — intervention group
Group type: COMPARATOR
Intervention: Standard pins (Orthofix)
Number of subjects: 50
Study 21419560 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compressions using the LUCAS™ device
Number of subjects: 149
Study 21419560 — intervention group
Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 149
Study 16272188 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg/day
Number of subjects: 14
Study 16272188 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg/day
Number of subjects: 14
Study 16272188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide-CFC
Number of subjects: 156
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone-CFC
Number of subjects: 156
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone-CFC
Number of subjects: 156
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone DPI
Number of subjects: 156
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide DPI
Number of subjects: 156
Study 12016099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone-CFC MDI
Number of subjects: 156
Study 12016099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10085995 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal, multimodal (ATVV) stimulation paired with line singing of Brahms' Lullaby, provided for 15‐30 minutes, one or two times per week from referral to discharge.
Number of subjects: 40
Study 10085995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 40
Study 10085995 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal, multimodal (ATVV) stimulation paired with line singing of Brahms' Lullaby.
Number of subjects: 40
Study 8067594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 8067594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3339718 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (80 mEq. per day)
Number of subjects: 6
Study 3339718 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate (80 mEq. per day)
Number of subjects: 6
Study 28885392 — intervention group
Group type: EXPERIMENTAL
Intervention: External thermomechanical stimulation using Buzzy
Number of subjects: 218
Study 28885392 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction via DistrACTION Cards
Number of subjects: 218
Study 28885392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of external thermomechanical stimulation and distraction
Number of subjects: 218
Study 28885392 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 218
Study 29471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Live supervision using Teleconferencing
Number of subjects: 97
Study 29471927 — intervention group
Group type: COMPARATOR
Intervention: Tape-based supervision
Number of subjects: 97
Study 29471927 — intervention group
Group type: COMPARATOR
Intervention: Workshop only
Number of subjects: 97
Study 26979712 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (four 200 ml coffee beverages containing 160 mg caffeine)
Number of subjects: 40
Study 26979712 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 40
Study 25572571 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin with concurrent thoracic radiation (SCCR)
Number of subjects: 40
Study 25572571 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone with concurrent thoracic radiation (CCR)
Number of subjects: 40
Study 23702705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70
Study 23702705 — intervention group
Group type: COMPARATOR
Intervention: Epidural block (EP)
Number of subjects: 70
Study 20339174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 0
Study 20339174 — intervention group
Group type: COMPARATOR
Intervention: Classic pancreaticoduodenectomy (PD)
Number of subjects: 0
Study 18821628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% midazolam formulation (MDG) - 1.0 mg total dose, intranasally into each nostril
Number of subjects: 108
Study 18821628 — intervention group
Group type: COMPARATOR
Intervention: 1% midazolam formulation (UDG) - 1.0 mg total dose, intranasally into one nostril
Number of subjects: 108
Study 18821628 — intervention group
Group type: COMPARATOR
Intervention: 1% midazolam formulation (UDG)
Number of subjects: 108
Study 18821628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% midazolam formulation (MDG)
Number of subjects: 108
Study 16610379 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterproof cast liner
Number of subjects: 59
Study 16610379 — intervention group
Group type: COMPARATOR
Intervention: Cotton cast liner
Number of subjects: 59
Study 12801285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite + EDTA
Number of subjects: 36
Study 12801285 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 36
Study 12801285 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine
Number of subjects: 36
Study 12801285 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 36
Study 10817583 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of depression predicted by superior frontal and superior parietal hypointense TI lesions
Number of subjects: 48
Study 10817583 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depression predicted by superior frontal, superior parietal and temporal TI lesions, lateral and third ventricular enlargement, and frontal atrophy
Number of subjects: 48
Study 10817583 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSS weakly predictive of presence of depression
Number of subjects: 48
Study 10817583 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSS weakly predictive of severity of depression
Number of subjects: 48
Study 10817583 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression not related to bright T2 lesions or enhancement
Number of subjects: 48
Study 8899495 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course triple therapy (bismuth subsalicylate two tablets four times daily, amoxicillin 1 g twice daily, metronidazole 500 mg four times daily)
Number of subjects: 34
Study 8899495 — intervention group
Group type: COMPARATOR
Intervention: High-dose omeprazole (40 mg twice a day) with amoxicillin (1 g twice a day)
Number of subjects: 34
Study 1665778 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.75 mg/70 kg i.m.)
Number of subjects: 6
Study 1665778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (30 mg i.m.)
Number of subjects: 6
Study 1665778 — intervention group
Group type: COMPARATOR
Intervention: Naloxone challenge at 24 h post-methadone
Number of subjects: 6
Study 1665778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 6
Study 6881268 — intervention group
Group type: EXPERIMENTAL
Intervention: Silcon contact lenses
Number of subjects: 10
Study 6881268 — intervention group
Group type: COMPARATOR
Intervention: Polycon II contact lenses
Number of subjects: 10
Study 30595323 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen (DR) atorvastatin therapy (10 mg for 12 weeks)
Number of subjects: 61
Study 30595323 — intervention group
Group type: COMPARATOR
Intervention: Every other day regimen (EODR) atorvastatin therapy (10 mg for 12 weeks)
Number of subjects: 61
Study 30595323 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen (DR) atorvastatin therapy
Number of subjects: 61
Study 30595323 — intervention group
Group type: COMPARATOR
Intervention: Every other day regimen (EODR) atorvastatin therapy
Number of subjects: 61
Study 27448477 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading from an iPad
Number of subjects: 16
Study 27448477 — intervention group
Group type: COMPARATOR
Intervention: Reading from a book
Number of subjects: 16
Study 25039318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (150 mg daily for 4 weeks)
Number of subjects: 16
Study 25039318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22674920 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet based vestibular rehabilitation with telephone support
Number of subjects: 337
Study 22674920 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet based vestibular rehabilitation only
Number of subjects: 337
Study 22674920 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 337
Study 20728505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on bur-cut dentin with polyalkenoic-acid conditioner
Number of subjects: 48
Study 20728505 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC (GC) applied on bur-cut dentin without polyalkenoic-acid conditioner
Number of subjects: 48
Study 20728505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on fractured dentin with or without conditioner
Number of subjects: 48
Study 20728505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on laser-irradiated dentin with or without conditioner
Number of subjects: 48
Study 18755999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topic links
Number of subjects: 90
Study 18755999 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific links
Number of subjects: 90
Study 18755999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 15755829 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (HP) - 5 g . kg(‐1) . d(‐1)
Number of subjects: 8
Study 15755829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate protein intake (IP) - 3 g . kg(‐1) . d(‐1)
Number of subjects: 8
Study 15755829 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein intake (NP) - 1.5 g . kg(‐1) . d(‐1)
Number of subjects: 8
Study 14749241 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 0.5 mg daidzein for 1 year)
Number of subjects: 205
Study 14749241 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement
Number of subjects: 205
Study 14749241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11532845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid
Number of subjects: 112
Study 11532845 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 9280173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus strength training
Number of subjects: 65
Study 9280173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus aerobic training
Number of subjects: 65
Study 9280173 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 65
Study 8348874 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (2.0, 4.0, and 8.0 micrograms/kg)
Number of subjects: 0
Study 8348874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.25, 0.5, 1.0 g/kg)
Number of subjects: 0
Study 8348874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3522444 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (CT) injection and placebo tablets
Number of subjects: 47
Study 3522444 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate (Pi) tablets and placebo injection
Number of subjects: 47
Study 3522444 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (CT) injection and phosphate tablets
Number of subjects: 47
Study 3522444 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection and placebo tablets (Control group)
Number of subjects: 47
Study 29518432 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized immunonutrition
Number of subjects: 29
Study 29518432 — intervention group
Group type: COMPARATOR
Intervention: Oral nutritional supplement
Number of subjects: 29
Study 27737377 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided physical activity three times a week and health education once a week for 16 weeks
Number of subjects: 33
Study 27737377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 33
Study 24719064 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) treatment for 8 weeks followed by maintenance regimens (twice weekly or tapering regimen)
Number of subjects: 0
Study 24719064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering regimen of TC
Number of subjects: 0
Study 24719064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly regimen of TC
Number of subjects: 0
Study 23072083 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture neurostimulation therapy
Number of subjects: 48
Study 20102355 — intervention group
Group type: EXPERIMENTAL
Intervention: High FODMAP diet
Number of subjects: 12
Study 20102355 — intervention group
Group type: COMPARATOR
Intervention: Low FODMAP diet
Number of subjects: 12
Study 18664995 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based psychoeducation and skills intervention (tier 1)
Number of subjects: 127
Study 18664995 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based intervention and 17-session manual-based group therapy intervention (tier 2)
Number of subjects: 127
Study 16620333 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 150
Study 16620333 — intervention group
Group type: COMPARATOR
Intervention: KY Jelly (standard lubricant)
Number of subjects: 150
Study 12651637 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 12
Study 12651637 — intervention group
Group type: COMPARATOR
Intervention: HES 70/0.5
Number of subjects: 12
Study 12651637 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 12
Study 10102960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, metronidazole 400 mg, and clarithromycin 250 mg (OMC)
Number of subjects: 149
Study 10102960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg (OAC)
Number of subjects: 149
Study 10102960 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (O)
Number of subjects: 149
Study 7786051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 ppm ozone during 1-h continuous exercise
Number of subjects: 12
Study 7786051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 ppm ozone during 2-h intermittent exercise
Number of subjects: 12
Study 7786051 — intervention group
Group type: COMPARATOR
Intervention: Filtered air during 1-h continuous exercise
Number of subjects: 12
Study 7786051 — intervention group
Group type: COMPARATOR
Intervention: Filtered air during 2-h intermittent exercise
Number of subjects: 12
Study 2129648 — intervention group
Group type: EXPERIMENTAL
Intervention: Algicon (10 ml four times daily)
Number of subjects: 20
Study 2129648 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon (20 ml four times daily)
Number of subjects: 20
Study 2129648 — intervention group
Group type: COMPARATOR
Intervention: Algicon
Number of subjects: 20
Study 2129648 — intervention group
Group type: COMPARATOR
Intervention: Gaviscon
Number of subjects: 20
Study 517118 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1-desamino-8-arginine vasopressin)
Number of subjects: 79
Study 517118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 31663311 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preventive warm-up
Number of subjects: 18
Study 31663311 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL rupture risk factor training
Number of subjects: 18
Study 31663311 — intervention group
Group type: COMPARATOR
Intervention: Inactive arm
Number of subjects: 18
Study 31663311 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 18
Study 29723106 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding treatment (n=45)
Number of subjects: 90
Study 29723106 — intervention group
Group type: COMPARATOR
Intervention: Sham catgut embedding treatment (n=45)
Number of subjects: 90
Study 27379904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-moderate exercise
Number of subjects: 220
Study 27379904 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 220
Study 24117676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique with subepithelial connective tissue graft (TUN)
Number of subjects: 24
Study 24117676 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) with enamel matrix derivative
Number of subjects: 24
Study 23081768 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-via-CALC program (telephone-based, 12-week)
Number of subjects: 45
Study 23081768 — intervention group
Group type: COMPARATOR
Intervention: LEARN Program for Weight Management (lifestyle modification treatment)
Number of subjects: 45
Study 21105279 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 150
Study 21105279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 18812659 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/d
Number of subjects: 50
Study 18812659 — intervention group
Group type: COMPARATOR
Intervention: lacidipine 4 mg/d
Number of subjects: 50
Study 18812659 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 50
Study 15762203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-warming lidocaine/tetracaine patch
Number of subjects: 100
Study 15762203 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 100
Study 12843889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin A
Number of subjects: 169
Study 12843889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporin A
Number of subjects: 169
Study 12843889 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 169
Study 10605527 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month seizure-free group (n = 41)
Number of subjects: 80
Study 10605527 — intervention group
Group type: COMPARATOR
Intervention: 24-month seizure-free group (n = 39)
Number of subjects: 80
Study 10605527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 80
Study 7572699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Exercise (DE)
Number of subjects: 20
Study 7572699 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 20
Study 1976052 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 10
Study 1976052 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1976052 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine
Number of subjects: 10
Study 1976052 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 10
Study 7031184 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylethylmalonamide 400 mg daily for one week
Number of subjects: 8
Study 7031184 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylethylmalonamide 800 mg daily for a second week
Number of subjects: 8
Study 7031184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 6710299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin
Number of subjects: 93
Study 6710299 — intervention group
Group type: COMPARATOR
Intervention: Systemic metronidazole and gentamicin
Number of subjects: 93
Study 31023274 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Reinforcement Therapy (CRT) combined with electronic self-monitoring (Monsenso Daybuilder System)
Number of subjects: 130
Study 31023274 — intervention group
Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 130
Study 31023274 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Reinforcement Therapy (CRT)
Number of subjects: 130
Study 30234645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 100
Study 30234645 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 100